David Balderson
About David Balderson
David Balderson serves as the Vice President of Pharmacovigilance and Renal Clinical Development at Travere Therapeutics, a position he has held since 2019. He has an extensive background in clinical safety and pharmacovigilance, with previous roles at GSK and Sciformix.
Work at Travere Therapeutics
David Balderson serves as the Vice President of Pharmacovigilance & Renal Clinical Development at Travere Therapeutics. He has held this position since 2019, contributing to the organization for five years. His role involves overseeing the safety and efficacy of renal therapies, ensuring compliance with regulatory standards, and leading clinical development initiatives. Based in the Greater San Diego Area, Balderson plays a key role in advancing the company's mission to improve patient outcomes through innovative treatments.
Education and Expertise
David Balderson studied at The University of Manchester, where he completed a PhD in Physiology & Pharmacology and earned a BSc. His academic journey spanned from 1989 to 1996, providing him with a strong foundation in the scientific principles underlying pharmacology and physiology. This educational background supports his expertise in pharmacovigilance and clinical development, particularly in the renal therapeutic area.
Background in Clinical Safety
Prior to his current role, David Balderson worked at GSK as the Manager of Global Clinical Safety & Pharmacovigilance from 1999 to 2005. During this six-year tenure in Greenford, UK, he was responsible for managing safety assessments and ensuring the integrity of clinical trials. Following his time at GSK, he served as Vice President of Global Safety Operations at Sciformix from 2015 to 2019 in California, USA, where he further developed his expertise in safety operations within the pharmaceutical industry.
Professional Experience at Sciformix
At Sciformix, David Balderson held the position of Vice President of Global Safety Operations from 2015 to 2019. His responsibilities included overseeing safety operations and enhancing pharmacovigilance processes. This role allowed him to leverage his extensive experience in clinical safety, contributing to the development of robust safety protocols and ensuring compliance with industry regulations.